GeneDx Shares Fall 16% as 2026 Growth Forecast Is Cut

GeneDx said late Monday that its quarterly loss widened to $12.3 million, or 41 cents a share, from $7.64 million, or 27 cents a share, a year earlier. Excluding one-time items, the company earned 28 cents a share, above the 7 cents analysts polled by FactSet had expected.

Revenue rose 5.5% to $123.1 million, edging past Wall Street estimates of $122.9 million. Revenue from exome and genome tests increased 12% to $110.4 million, while test-result volume climbed 25% to 32,134.

The company kept its full-year revenue forecast at $475 million to $490 million, compared with analysts’ estimate of $477.7 million. But its fourth-quarter revenue expectation of $135 million fell short of the $142.6 million expected by Wall Street.

For 2026, GeneDx now expects revenue growth in its exome and genome test business of at least 17%, down from its previous forecast of at least 20%. It also lowered its expected test-result volume growth to at least 28%, from at least 30%.